SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Krzysztof Piotr Bielawski, An initial assessment of correlations between host- and virus-related factors affecting analogues antiviral therapy in HBV chronically infected patients, Medical Science Monitor, 2014, 20, 321

    CrossRef

  2. 2
    Yuag-Meng Liu, Yu-Jen Cheng, Yu-Lin Li, Chun-Eng Liu, Wu-Huei Hsu, Antituberculosis Treatment and Hepatotoxicity in Patients with Chronic Viral Hepatitis, Lung, 2014, 192, 1, 205

    CrossRef

  3. 3
    Chun-Ying Wu, Jaw-Town Lin, Hsiu J. Ho, Chien-Wei Su, Teng-Yu Lee, Shen-Yung Wang, Chuhui Wu, Jaw-Ching Wu, Association of Nucleos(t)ide Analogue Therapy With Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B—A Nationwide Cohort Study, Gastroenterology, 2014, 147, 1, 143

    CrossRef

  4. 4
    Qunying Han, Na Li, Qianqian Zhu, Zhu Li, Guoyu Zhang, Jinghong Chen, Yi Lv, Yawen Wang, Zhengwen Liu, Chunqiu Hao, Association of serum soluble human leukocyte antigen-G levels with chronic hepatitis B virus infection, Clinical and Experimental Medicine, 2014, 14, 1, 35

    CrossRef

  5. 5
    Monika Sarkar, Valentina A. Shvachko, Joanna B. Ready, Mary Pat Pauly, Norah A. Terrault, Marion G. Peters, M. Michele Manos, Characteristics and Management of Patients with Chronic Hepatitis B in an Integrated Care Setting, Digestive Diseases and Sciences, 2014,

    CrossRef

  6. 6
    Seung In Seo, Hyeok Soo Choi, Bo Youn Choi, Hyoung Su Kim, Hak Yang Kim, Myoung Kuk Jang, Coexistence of hepatitis B surface antigen and antibody to hepatitis B surface may increase the risk of hepatocellular carcinoma in chronic hepatitis B virus infection: A retrospective cohort study, Journal of Medical Virology, 2014, 86, 1
  7. 7
    Jessica Liu, Hwai-I Yang, Mei-Hsuan Lee, Richard Batrla-Utermann, Chin-Lan Jen, Sheng-Nan Lu, Li-Yu Wang, San-Lin You, Chuhsing Kate Hsiao, Chien-Jen Chen, Distinct seromarkers predict different milestones of chronic hepatitis B progression, Hepatology, 2014, 60, 1
  8. 8
    Jian Qi Lian, Xiao Fei Yang, Rong Rong Zhao, Yan Yan Zhao, Yu Li, Ye Zhang, Chang Xing Huang, Expression Profiles of Circulating Cytokines, Chemokines, and Immune Cells in Patients With Hepatitis B Virus Infection, Hepatitis Monthly, 2014, 14, 5

    CrossRef

  9. You have free access to this content9
    Maria Buti, HBeAg-positive chronic hepatitis B: Why do I treat my patients with Nucleos(t)ide Analogs?, Liver International, 2014, 34,
  10. 10
    L-p Liu, B-g Hu, C Ye, R L K Ho, G G Chen, P B S Lai, HBx mutants differentially affect the activation of hypoxia-inducible factor-1α in hepatocellular carcinoma, British Journal of Cancer, 2014, 110, 4, 1066

    CrossRef

  11. 11
    Stephen C. Ko, Sarah F. Schillie, Tanja Walker, Steven L. Veselsky, Noele P. Nelson, Julie Lazaroff, Susan Crowley, Cristina Dusek, Khalilah Loggins, Kenneth Onye, Nancy Fenlon, Trudy V. Murphy, Hepatitis B vaccine response among infants born to hepatitis B surface antigen-positive women, Vaccine, 2014, 32, 18, 2127

    CrossRef

  12. 12
    Yin-Chu Chien, Chyi-Feng Jan, Chun-Ju Chiang, Hsu-Sung Kuo, San-Lin You, Chien-Jen Chen, Incomplete hepatitis B immunization, maternal carrier status, and increased risk of liver diseases: A 20-year cohort study of 3.8 million vaccinees, Hepatology, 2014, 60, 1
  13. 13
    Yuecheng Yu, Jinlin Hou, Masao Omata, Yue Wang, Lanjuan Li, Loss of HBsAg and antiviral treatment: from basics to clinical significance, Hepatology International, 2014, 8, 1, 39

    CrossRef

  14. 14
    Lily H. Kim, Vincent G. Nguyen, Huy N. Trinh, Jiayi Li, Jian Q. Zhang, Mindie H. Nguyen, Low Treatment Rates in Patients Meeting Guideline Criteria in Diverse Practice Settings, Digestive Diseases and Sciences, 2014,

    CrossRef

  15. 15
    M. Littlejohn, J. Davies, L. Yuen, R. Edwards, T. Sozzi, K. Jackson, B. Cowie, S. Tong, J. Davis, S. Locarnini, Molecular virology of hepatitis B virus, sub-genotype C4 in northern Australian Indigenous populations, Journal of Medical Virology, 2014, 86, 4
  16. 16
    Sima Besharat, Aezam Katoonizadeh, Abdolvahab Moradi, Potential Mutations Associated With Occult Hepatitis B Virus Status, Hepatitis Monthly, 2014, 14, 4

    CrossRef

  17. 17
    H. Leblebicioglu, V. Arama, X. Causse, P. Marcellin, R. Ozaras, B. Postawa-Klozinska, K. Simon, A. I. Suceveanu, M. Wiese, S. Zeuzem, I. Klauck, E. Morais, S. Bjork, B. Lescrauwaet, D. Kamar, J. P. Zarski, Predictors associated with treatment initiation and switch in a real-world chronic hepatitis B population from five European countries, Journal of Viral Hepatitis, 2014, 21, 9
  18. 18
    Philip R. Spradling, Lisa Bulkow, Eyasu H. Teshale, Susan Negus, Chriss Homan, Brenna Simons, Brian J. McMahon, Prevalence and causes of elevated serum aminotransferase levels in a population-based cohort of persons with chronic hepatitis B virus infection, Journal of Hepatology, 2014,

    CrossRef

  19. 19
    Nghiem B. Ha, Nghi B. Ha, Kevin T. Chaung, Huy N. Trinh, Huy A. Nguyen, Khanh K. Nguyen, Mindie H. Nguyen, Similar Response to Entecavir 0.5 and 1.0 Mg in Treatment-Naïve Chronic Hepatitis B Patients: A Case-Control Study, Digestive Diseases and Sciences, 2014, 59, 1, 168

    CrossRef

  20. 20
    S. Fiorino, E. Chili, L. Bacchi-Reggiani, M. Masetti, G. Deleonardi, A.G. Grondona, T. Silvestri, E. Magrini, N. Zanini, A. Cuppini, R. Nardi, E. Jovine, Association between hepatitis B or hepatitis C virus infection and risk of pancreatic adenocarcinoma development: A systematic review and meta-analysis, Pancreatology, 2013, 13, 2, 147

    CrossRef

  21. 21
    C-H Chiang, H-I Yang, C-L Jen, S-N Lu, L-Y Wang, S-L You, J Su, U H Iloeje, C-J Chen, Association between obesity, hypertriglyceridemia and low hepatitis B viral load, International Journal of Obesity, 2013, 37, 3, 410

    CrossRef

  22. 22
    J.-L. Hou, J.-D. Jia, L. Wei, W. Zhao, Y. M. Wang, M. Cheng, X. Tang, D.-M. Tan, H. Ren, H. Tang, D. Cohen, C. Llamoso, Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a ‘real-world’ clinical practice setting in China, Journal of Viral Hepatitis, 2013, 20, 11
  23. 23
    Y. Li, Y. Zhang, J.-P. Wang, J.-Q. Lian, X.-F. Bai, Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil, Journal of Viral Hepatitis, 2013, 20,
  24. 24
    U. Herbers, S. Amini-Bavil-Olyaee, A. Mueller, T. Luedde, C. Trautwein, F. Tacke, Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains, Journal of Viral Hepatitis, 2013, 20, 2
  25. 25
    Françoise Lunel-Fabiani, Wael Mansour, Abdellahi Ould Amar, Mohamed Aye, Frédéric Le Gal, F- Zahra Fall Malick, Lô Baïdy, Ségolène Brichler, Pascal Veillon, Alexandra Ducancelle, Emmanuel Gordien, Michel Rosenheim, Impact of hepatitis B and delta virus co-infection on liver disease in Mauritania: A cross sectional study, Journal of Infection, 2013, 67, 5, 448

    CrossRef

  26. 26
    William E. Delaney, Molecular virology of chronic hepatitis B and C: Parallels, contrasts and impact on drug development and treatment outcome, Antiviral Research, 2013, 99, 1, 34

    CrossRef

  27. 27
    Chia-Hsuin Chang, Jou-Wei Lin, Li-Chiu Wu, Chia-Hong Liu, Mei-Shu Lai, National Antiviral Treatment Program and the Incidence of Hepatocellular Carcinoma and Associated Mortality in Taiwan, Medical Care, 2013, 51, 10, 908

    CrossRef

  28. 28
    Chih-Lin Lin, Jia-Horng Kao, Risk stratification for hepatitis B virus related hepatocellular carcinoma, Journal of Gastroenterology and Hepatology, 2013, 28, 1
  29. 29
    Ye Zhang, Jian-Qi Lian, Yu Li, Jie-Pin Wang, Chang-Xing Huang, Xue-Fan Bai, Jiu-Ping Wang, Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine, European Journal of Gastroenterology & Hepatology, 2013, 25, 7, 814

    CrossRef

  30. 30
    R. S. Tedder, A. J. Rodger, L. Fries, S. Ijaz, M. Thursz, W. Rosenberg, N. Naoumov, J. Banatvala, R. Williams, G. Dusheiko, S. Chokshi, T. Wong, G. Rosenberg, S. Moreea, M. Bassendine, M. Jacobs, P. R. Mills, D. Mutimer, S. D. Ryder, A. Bathgate, H. Hussaini, J. F. Dillon, M. Wright, G. Bird, J. Collier, M. Anderson, A. M. Johnson, The Diversity and Management of Chronic Hepatitis B Virus Infections in the United Kingdom: A Wake-up Call, Clinical Infectious Diseases, 2013, 56, 7, 951

    CrossRef

  31. You have free access to this content31
    Hong Ma, Jidong Jia, Why do I treat HBeAg-positive chronic hepatitis B patients with a Nucleoside analogue, Liver International, 2013, 33,
  32. 32
    Stephanos J. Hadziyannis, Dimitrios Vassilopoulos, Emilia Hadziyannis, Antiviral Agents, 2013,

    CrossRef

  33. 33
    Simona Cosconea, Hélène Fontaine, Jean-François Méritet, Marion Corouge, Philippe Sogni, Anais Vallet-Pichard, Vincent Mallet, Christophe Legendre, Stanislas Pol, Benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection, Journal of Hepatology, 2012, 57, 1, 55

    CrossRef

  34. 34
    Jörg Petersen, Maria Buti, Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs, Expert Review of Gastroenterology & Hepatology, 2012, 6, 6, 683

    CrossRef

  35. 35
    S. Pol, P. Lampertico, First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice, Journal of Viral Hepatitis, 2012, 19, 6
  36. 36
    Chun-Hui Yan, Cheng-Yu Zhao, Hai Ding, Ya-Qin Peng, Peng-Yuan Jin, Ling Yan, Hui Zhuang, Tong Li, Hepatitis B virus basal core promoter mutations A1762T/G1764A are associated with genotype C and a low serum HBsAg level in chronically-infected HBeAg-positive Chinese patients, Antiviral Research, 2012, 96, 2, 108

    CrossRef

  37. 37
    Grace L-H Wong, How does hepatitis B virus infection react to hepatocellular carcinoma treatment?, Journal of Gastroenterology and Hepatology, 2012, 27, 1
  38. 38
    Frank Tacke, Elham Shirvani-Dastgerdi, Impact of Drug-Resistance Polymerase Mutations on the Replication of HBeAg-Positive and HBeAg-Negative Hepatitis B Virus Strains in Vitro, Hepatitis Monthly, 2012, 12, 6, 357

    CrossRef

  39. 39
    Hwai–I Yang, Hsiu–Lian Hung, Mei–Hsuan Lee, Jessica Liu, Chin–Lan Jen, Jun Su, Li–Yu Wang, Sheng–Nan Lu, San–Lin You, Uchenna H. Iloeje, Chien–Jen Chen, Incidence and Determinants of Spontaneous Seroclearance of Hepatitis B e Antigen and DNA in Patients With Chronic Hepatitis B, Clinical Gastroenterology and Hepatology, 2012, 10, 5, 527

    CrossRef

  40. 40
    Jin-Kyoung Oh, Hai-Rim Shin, Min Lim, Heeyoun Cho, Dong-Il Kim, Youngmee Jee, Haesun Yun, Keun-Young Yoo, Multiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and C co-infected subjects in HBV endemic area: a community-based cohort study, BMC Cancer, 2012, 12, 1, 452

    CrossRef

  41. 41
    Uchenna H Iloeje, Hwai-I Yang, Chien-Jen Chen, Natural history of chronic hepatitis B: what exactly has REVEAL Revealed?, Liver International, 2012, 32, 9
  42. 42
    Shannan R. Tujios, William M. Lee, New advances in chronic hepatitis B, Current Opinion in Gastroenterology, 2012, 28, 3, 193

    CrossRef

  43. 43
    Michael Chang, Sammy Saab, Interferon for Hepatitis B: Which Populations Benefit the Most, Current Hepatitis Reports, 2011, 10, 4, 285

    CrossRef

  44. 44
    Jann-Yuan Wang, Chen-Hua Liu, Fu-Chang Hu, Hsiu-Ching Chang, Jia-Luen Liu, Jong-Min Chen, Chong-Jen Yu, Li-Na Lee, Jia-Horng Kao, Pan-Chyr Yang, Risk factors of hepatitis during Anti-tuberculous treatment and implications of hepatitis virus load, Journal of Infection, 2011, 62, 6, 448

    CrossRef

  45. 45
    Myron J. Tong, Calvin Q. Pan, Hie-Won Hann, Kris V. Kowdley, Steven-Huy B. Han, Albert D. Min, Truong-Sinh Leduc, The Management of Chronic Hepatitis B in Asian Americans, Digestive Diseases and Sciences, 2011, 56, 11, 3143

    CrossRef